Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

被引：4
|
作者：
Soumerai, Jacob D. [1 ]
Diefenbach, Catherine S. [2 ]
Samaniego, Felipe [3 ]
Kumar, Abhijeet [4 ]
Tsai, Michaela L. [5 ]
Asch, Adam S. [6 ]
Jagadeesh, Deepa [7 ]
Kenkre, Vaishalee P. [8 ]
Lossos, Izidore S. [9 ]
Salman, Huda [10 ]
Awan, Farrukh T. [11 ]
Miao, Lu [12 ]
Ghalie, Richard G. [12 ]
Zelenetz, Andrew D. [13 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Lymphoma, Boston, MA 02114 USA
[2] NYU, Sch Med, NYU Canc Inst, New York, NY USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[4] Univ Arizona, Ctr Canc, Div Hematol & Oncol, Tucson, AZ USA
[5] Swedish Canc Inst, Seattle, WA USA
[6] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[7] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
[8] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[9] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA
[10] Stony Brook Univ Hosp, Stony Brook, NY USA
[11] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[12] MEI Pharma Inc, San Diego, CA USA
[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-157563
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS FOR ACALABRUTINIB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL) IN CHINA
    Chang, S.
    He, X.
    VALUE IN HEALTH, 2024, 27 (06) : S95 - S95
  • [42] Efficacy of PI3K-inhibitors in Mantle Cell Lymphoma (MCL)
    Zoellner, A. -K.
    Arndt, J.
    Hutter, G.
    Zimmermann, Y.
    Hiddemann, W.
    Dreyling, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 72 - 72
  • [43] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)
    Mehta, Amitkumar
    Trneny, Marek
    Walewski, Jan
    Ribrag, Vincent
    Dartigeas, Caroline
    Christensen, Jacob Haaber
    Pane, Fabrizio
    Rodriguez, Guillermo
    Taszner, Michal
    Venugopal, Parameswaran
    Zilioli, Vittorio Ruggero
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Zinzani, Pier Luigi
    BLOOD, 2020, 136
  • [44] Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma
    Eltantawy, Adel
    Vallejos, Ximena
    Sebea, Elrodia
    Evans, Kirsten
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (09) : 954 - 958
  • [45] Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
    Pagel, John
    Morschhauser, Franck
    Herve, Tilly
    Chaidos, Aristeidis
    Phillips, Tycel
    Ribrag, Vincent
    Campbell, Phillip
    Fruchart, Christophe
    Jurczak, Wojciech
    McKay, Pamela
    Opat, Stephen
    Radford, John
    McDonald, Alice
    Howell, Haley
    Newberry, Kate
    Woodruff, Mark
    Clawson, Alicia
    Larus, John
    Blakemore, Stephen
    Miao, Harry
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S278 - S279
  • [46] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL)
    Krekeler, G.
    Dreyling, M.
    Hess, G.
    Kalanovic, D.
    ONKOLOGIE, 2011, 34 : 269 - 269
  • [47] Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    De Vos, Sven
    Furman, Richard R.
    Barrientos, Jacqueline C.
    Wagner-Johnston, Nina D.
    Flinn, Ian
    Sharman, Jeff P.
    Boyd, Thomas
    Leonard, John P.
    Dansey, Roger
    Kim, Yeonhee
    Holes, Leanne M.
    Dubowy, Ronald L.
    Coutre, Steven E.
    BLOOD, 2013, 122 (21)
  • [48] Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL).
    O'Connor, OA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 578S - 578S
  • [49] Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
    Dreyling, M.
    Morschhauser, F.
    Bouabdallah, K.
    Bron, D.
    Cunningham, D.
    Assouline, S. E.
    Verhoef, G.
    Linton, K.
    Thieblemont, C.
    Vitolo, U.
    Hiemeyer, F.
    Giurescu, M.
    Garcia-Vargas, J.
    Gorbatchevsky, I.
    Liu, L.
    Koechert, K.
    Pena, C.
    Neves, M.
    Childs, B. H.
    Zinzani, P. L.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2169 - 2178
  • [50] Phase I/II study to evaluate the safety and efficacy of tenalisib, a novel PI3K δ/γ dual inhibitor in combination with pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma.
    Ramchandren, Rod
    Lynch, Ryan C.
    Barde, Prajak J.
    Nair, Ajit
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345